Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study

Real-World Clinical Outcomes with First-Line Systemic Treatment and Avelumab Maintenance in US Patients with Locally Advanced or Metastatic Urothelial Carcinoma: The SPEAR Bladder-II Study

Avelumab first-line maintenance (1LM) is approved for patients with locally advanced or metastatic urothelial carcinoma (la/mUC) who do not have disease progression after platinum-based chemotherapy (PBC). This retrospective study describes real-world treatment patterns and clinical outcomes in pati...

Full description

Saved in:
Bibliographic Details
Main Authors: Sneha Sura, Manojkumar Bupathi, Valerie Morris, Paul Conkling, Karen Todoroff, Abhijeet Bhanegaonkar, Chiemeka Ike
Format: Article
Language:English
Published: MDPI AG 2025-03-01
Series:Current Oncology
Subjects:
avelumab
first-line maintenance
locally advanced or metastatic urothelial cancer
overall survival
real-world time to next treatment
real-world time to treatment discontinuation
Online Access:https://www.mdpi.com/1718-7729/32/4/187
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/1718-7729/32/4/187

Similar Items